"Systems and MEthods for Accurately Estimating Cutaneous Water Losses in Response to Exercise"
IP Approach is pleased to present the exclusive patent for sale or license “Systems and methods for accurately estimating cutaneous water losses in response to exercise” which includes U.S. Granted Patent US 11,219,410 B2 and its foreign counterparts JP 2019519340 A, MX 2018011495 A, CN 109068989 A and WO 2017165037 A1 assigned to Sports Science Synergy LLC. The IP relates to accurately estimating water losses from the skin in response to exercise by use of an equation that integrates air temperature and energy expenditure alone as required inputs.
The technology disclosed provides the following advantages:
- The invention provides a method to know one’s individual rates of cutaneous water loss for given circumstances and tailor drinking behaviors to avoid over-drinking and under-drinking thus optimizing health and performance.
- The invention accurately predicts individual exercise fluid needs (i.e., sweat losses).
- The invention provides athletes, coaches, researchers, and industry with a simple and accurate means of estimating exercise sweat losses to better manage athlete hydration.
- The invention predicts sweat losses before, during, and after exercise.
- The invention can be used to forecast sweat losses in different venues, thus adding product value and end-user appeal to sports wearables, fitness apps, sweat patches, and smart bottles.
- The invention is easily integrated directly into existing sports wearables and fitness app platforms or using a variety of DevOps (e.g., API, SDK).
- The invention allows accurate (> 90% accuracy) estimates of whole body sweat electrolyte losses from the product of local patch sweat [electrolyte] measurements and accurate whole body sweat loss predictions.
- The invention sweat loss predictions are the perfect complement to sports beverage and fluid delivery businesses aiming to optimize and personalize athlete hydration.
- The invention provides the missing link for on-demand, bespoke hydration when combined with novel fluid intake tracking and personal sweat electrolyte profiles.
- The invention is easily incorporated into existing sports wearables or fitness app platforms.
- The invention is a natural complement to sweat patch and smart fluid delivery technologies.
- The invention improves performance (reduce dehydration) and sustain health (reduce hyponatremia risk).
The global Dehydration Monitoring Systems market is estimated to grow from USD 2.25 billion in 2023 to USD 3.5 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 6.5% during the forecast period.
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
"Composition for Treatment, Inhibition and Attenuation of Virus"
IP Approach is pleased to present the exclusive patent for sale or license “Composition for treatment, inhibition and attenuation of virus” which includes U.S. Granted Patent US 9,694,030 B2 assigned to Sawaya Medical Patents LLC. The IP generally relates to pharmaceutical medication composition for the treatment of viral infections, and particularly to an pharmaceutical formulation for treatment, inhibition and attenuation of viruses in human beings.
The invention disclosed provides the following advantages:
- The invention can be used against the plurality of virus including ebola virus, herpes virus, dengue virus, smallpox virus, measles virus, mumps rubella virus, HIV (human immunodeficiency virus), lassa fever virus, yellow fever virus, cancer and solid tumors, especially the fibrosarcoma tumor.
- The invention composition could be given orally, intravenously, inhalation, intravesical, vaginal, rectal, sublingual, ophthalmic, or topical and was tested by UBC 2016.
- The invention sodium thiosulfate (STS) is used for treating neurodegenerative disorders that has a prominent neuro-inflammatory component.
- The cost of invention sodium thiosulfate (STS) IV or oral could be to treat Sarcoma is 100 times less than any known treatment in the world.
- The invention is unique and offers a proven way for –H2S (hydrogen sulfide) being safe for human, copious amounts of H2S to bind metals in humans and in the environment, water and animals and killing viruses and cancers and more.
The global market of Sodium Thiosulphate is to grow from USD 96.36 million in 2021 and is expected to reach USD 159.48 million in 2029, growing at a compounded annual growth rate (CAGR) of 6.5% during the forecast period.
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
"Cyclic Poly L-Latic Acid"
IPApproach, LLC is pleased to present the exclusive patent for sale “Cyclic poly L-lactic acid” which includes U.S. Granted Patent US 10,954,336 B2 assigned to SCRUM Co. Ltd. The IP relates to a cyclic poly L-lactic acid (composition) having a specific pH by the polymer itself (alone), a method for producing the same, a pharmaceutical product containing the cyclic poly L-lactic acid (composition) and the like.
The technology disclosed provides the following advantages:
- The invention substance is a kind of a regulatory substance secreted from the cell, which is taken into the body and involved in the improvement of cell functions.
- The invention substance has various medical uses such as a metabolic regulator, a metabolic inhibitor, an immune activator (for example, activator of immune cells such as NK cells), an inhibitor of LDH activity of a cancer cell, an inhibitor/suppressor of the growth of a cancer cell and a cancer therapeutic agent.
- The invention substance is a biodegradable and bio-absorbable substance, and is involved in the generation of intracellular energy in the body.
- The invention substance has a low molecular weight of 2,000 or less, and is used in pharmaceuticals, foods, drinking water, and health foods.
- The invention substance can be administrated orally as oral powder, tablets, capsules, and parenterally drops, injections, poultices, and the like.
- The invention substance does not have acidity therefore it does not require a neutralizing agent or sweetener, and is easy to process and to ingest.
The global polylactic acid market is estimated to grow from USD 0.57 billion in 2020 to USD 2.5 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 15.9% during the forecast period.
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
"Smartwatch-type Individual Medical Monitoring Device And Method For Individual Medical Monitoring Of A User Thereof"
IP Approach is pleased to present the exclusive patents for sale “Smartwatch-type Individual Medical Monitoring Device and Method for Individual Medical Monitoring of A User Thereof” which includes U.S. Patent Applications US 2021/0330199 A1 & US 2021/0330257 A1 and foreign counterpart application EP21169927A, assigned to Samira Kerrouche & Hayame Bouyahia.
The IP relates to a method, for individual medical monitoring configured to come into contact with the wrist of the user.
The technology disclosed provides the following advantages:
- The medical monitoring device could be worn by the user continuously providing continuous reliable medical supervision so that the patients could benefit from adequate response to symptoms.
- The measurement unit of the medical device is present on the radial artery of the user allowing the device to obtain reliable data and perform analyses on accurate data.
- The medical monitoring device has multiple sensors and processor so that the data can be cross checked which enhances the device reliability.
- The device has a unique identification means which allows securing the data contained in the device so that the data is not accessible to everyone.
The Wearable medical device market is estimated to grow from USD 27.28 billion in 2022 to USD 197.81 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 28.1% during the forecast period.
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
"Dietary Regime for Treatment of Acne"
IP Approach is pleased to present the exclusive patent portfolio for sale “Dietary regime for treatment of acne” which includes U.S. Granted Patents US 10,650,064 B2 & US 11,328,621 B2 and foreign counterparts AU 2014338690 B2, WO 2015059561 A1, CN 105764518 A, EP 3060222 A1 & HK 1221179 A1 assigned to Red Pinnace Ltd. The present invention relates to methods for controlling or preventing acne and other inflammatory skin conditions in humans.
The technology disclosed provides the following advantages:
- The invention provides a method to prevent overuse of topical medications, cleansers, or astringents that can often worsen a patient's condition or cause adverse clinical events particularly in the case of oral retinoids.
- The invention provides the list of food products forming part of the diet that on a display of a communication device, allows selection of the one or more food product from the list to form a daily diet list and/or provides feedback.
- The invention provides a database of information relating to the content of fructose, oligosaccharides and/or polyol sugars in a plurality of food products residing on a server computer. Thus allowing user to make food selection and calculates the total content of fructose, oligosaccharides and/or polyol sugars in the selected one or more food product.
- The invention enables to be used to cure acne and inflammatory skin disorder such as acne rosacea, general erythema, poikaderma de Civette, eczema.
Global market of skin health foods is estimated to grow from USD 1.7 billion in 2018 to USD 3.41 billion by 2028, at a Compound Annual Growth Rate (CAGR) of 7.2% during the forecast period.
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
"Lotion Applicator"
IP Approach is pleased to present the exclusive patents for sale “Lotion applicator” which includes U.S. patent application US 20120093561 A1 and its foreign counterpart patent application CA 2848450 A1 assigned to Barbara Swick. The IP relates to an apparatus for applying lotion.
The technology disclosed provides the following advantages:
- The apparatus helps to apply a lotion, ointment or other fluid, such as sunscreen and moisturizer, to one or more parts of the body without assistance.
- The apparatus helps people with a limited range of motion in the arms due to injury or age to apply lotion on their back.
- The apparatus includes two narrow rope loops for grabbing and placing the applicator on the back. The applicator is, also, useful for applying lotions, creams, exfoliants or ointments to other body parts with little waste due to the non-absorbent fabric(Polyvinyl & Nylon).
- Environment friendly
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
“Independently Adjusting, Multi-Legged Walking Cane”
IPApproach, LLC is pleased to present the exclusive patents for sale “Independently Adjusting, Multi-Legged Walking Cane” which includes U.S. Granted Patent US 8,607,809 assigned to Simon Chen.
The invention is a multi-legged walking cane where each leg operates independently of each other by employing compressible legs, enhancing stability thru the complete gait cycle.
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
“In Vivo Micro-invasive Investigation Device Including a Metal Guide”
IP Approach is pleased to present the exclusive patents for license “In vivo micro-invasive investigation device including a metal guide” which includes U.S. Granted Patent US 8,969,010 B2 and its foreign counterparts EP 2095762, CH 2095762, DE 2095762, ES 2095762, FR 2095762, GB 2095762, IT 2095762, NL 2095762, PT 2095762, SE 2095762, TR 2095762, WO 2009106295, CA 2716751, CN ZL200980112079.4, IN 341730, JP 5620277, KR 10-1624755, CN ZL201410136896.6, HK 1155928, HK 1195231, MO J/002917 assigned to Biostems Ltd. The present invention concerns the functionalization of a transparietal investigation device, a method of ex-vivo analysis of a substrate using a functionalized device of the invention and the use of such a device for the fabrication of a tool for the diagnosis of a cancer, an infection, an inflammation, a neurodegenerative disease or graft rejection in a patient.
The technology disclosed provides the following advantages:
- The device causes weak traumatism to the patient that allows to carry out several micro-analyses or micro-samplings to a patient at regular intervals to follow the evolution of a cancer, an inflammation, an infection, a neurodegenerative disease or the good graft retention of an organ in a patient.
- The device has spots formed by the structuration of the surface and are situated at the surface of the guide so that these spots are directly in contact with the fluids, the tissues and the cells.
- The device diameter at its extremity is weak enough to allow the simplified navigation in the blood circulation or in the natural cavities.
- The device, because of the use of a metallic guide, is rigid enough at its functionalized extremity to efficiently perforate a tissue or an organ.
- Because of the nature of the metallic guide, the device presents an improved imagery signal that simplify the radioguidance of the device at the time of the intervention to the target tissue or organ.
- The device can be associated with an optical fiber instead of metallic guide allowing a fine in situ visualization, in view of the in vivo capture of the elements necessary to the diagnostic and eventually to the prognosis evaluation.
- The optical fiber properties can be used with the device for the purpose of marking imagery and of setting of the device from the in situ visualization.
The Endoscopy Devices market was valued at USD 31.78 billion in 2019 and is expected to reach USD 43.83 billion in 2027, growing at a compounded annual growth rate (CAGR) of 4.1% during the forecast period. The Biopsy Devices market was valued at USD 2.23 billion in 2019 and is expected to reach USD 3.61 billion in 2027, growing at a compounded annual growth rate (CAGR) of 6.2% during the forecast period.
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
"Bleeding Control Device and Method of Manufacture and Use"
IPApproach LLC is pleased to present the exclusive patents for sale “Bleeding Control Device And Method Of Manufacture And Use” which includes U.S. Patent Application US 2021/0244625 A1 assigned to Ryan L. Reese. The IP relates to bleeding control devices, including bleeding control devices used for root canal procedures.
The technology disclosed provides the following advantages:
- The bleeding control device can be used intraoperative during dental root canal procedures.
- The device can be used to reduce and control bleeding during endodontic surgery, endodontic microsurgery, endodontic procedures such as root canal procedures and other types of surgeries and medical procedures.
- The device provides a sufficient area to be held by its operator while inserting the application portion into the pulp chamber PC and the root canal(s) RC to apply the solute.
- The device can be provided in non-standardized sizes continue such as Extra Course (XC), Course (C), Medium (M), Fine (F), and Extra Fine (XF), with Extra Course being the largest and Extra Fine being the smallest.
- The device’s applicator comprises of a core that provides rigidity to the applicator and an outer layer that may hold (e.g., absorb) the solution so that it may be applied during the root canal procedure as required.
The Root Canal market was valued at USD 1.02 Billion in 2021 and is expected to reach USD 1.39 Billion in 2028, growing at a compounded annual growth rate (CAGR) of 4.5% during the forecasted period.
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
"Drug for Treatment of Colon Cancer"
IPApproach, LLC is pleased to present the exclusive patents for sale “Drug For Treatment Of Colon Cancer” which includes U.S. Granted Patents US 8,329,756 B2 & US 8,518,990 B2 assigned to Oncophor LLC. The IP relates to the discovery of two new chemicals that can be used for the treatment, prevention, or amelioration of hyperproliferative diseases and/or disorders such as colon cancer. The technology disclosed provides the following advantages: 
- It provides a method for treating, preventing, or ameliorating a hyperproliferative disease and/or disorder such as cancer with minimal or none of the side effects often associated with chemotherapy.
- It provides a method of not killing normal reproducing cells while treatment.
- The method helps to inhibit cancer cell proliferation and demonstrates significant absence of side effects, low toxicity, superior bioavailability in general (such as e.g. good internal absorption), superior therapeutic window and beneficial effects related to their therapeutic and pharmaceutical suitability.
- Utilizing the compounds specified in the method helps to avoid side effects from chemotherapy including, gastrointestinal toxicity such as early and late-forming diarrhea and flatulence; nausea; vomiting; anorexia; leukopenia; anemia; neutropenia; asthenia; abdominal cramping; fever; pain; loss of body weight; dehydration; alopecia; dyspnea; insomnia; dizziness, mucositis, xerostomia, and kidney or renal failure, as well as constipation, nerve and muscle effects, temporary or permanent damage to kidneys and bladder, flu-like symptoms, fluid retention, and temporary or permanent infertility.
The global colorectal cancer therapeutics market is estimated to grow from USD 10.72 billion in 2020 to USD 16.64 billion by 2026, at a Compound Annual Growth Rate (CAGR) of 7.6% during the forecast period. The global oncology/cancer drugs market is estimated to grow from USD 128.45 billion in 2020 to USD 217.91 billion by 2028, at a Compound Annual Growth Rate (CAGR) of 6.83% during the forecast period.
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
"Non-Invasive Substance Concentration Measurement Using an Optical Bridge"
IP Approach is pleased to present the exclusive patents for sale “Non-invasive substance concentration measurement using and optical bridge” which includes U.S. Granted Patents US 10,219,755 B2; US 8,175,666 B2 & US 7,003,337 B2 assigned to Valoa Technologies Inc. The IP relates to a method for non-invasive measurement of the concentration of target analytes in body tissues.
The technology disclosed provides the following advantages:
- Non-invasive measurement of glucose offers the potential for increased frequency of testing and more responsive control of blood glucose concentrations through concomitant adjustment of insulin doses.
- Non-invasive detection techniques also offer the potential for accurate, portable, closed-loop systems for monitoring and regulating insulin dosage without an indwelling sensor.
- Post-Balancing is done after the measurement data is acquired and analyzed, therefore, it can be tuned to each measurement, and iterated until the required balancing criteria are reached.
- Provides the fastest possible blood content change.
- Provides a good sensitivity to blood.
- Capable of improving accuracy of target analyte concentration estimation.
- Generates the required combined beam without a wavelength-tunable light source.
- The sample provides the advantage of minimizing the effects of the variation in the scattering properties of the sample.
The non-invasive blood glucose monitoring devices market size was valued at USD 14.15 Million in 2020. The market size will reach USD 124.23 Million by the end of 2028, growing at a CAGR of 31.20% during 2020 to 2028.
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
“Retraction Devices and Methods of its Use and Manufacture"
IPApproach, LLC is pleased to present the exclusive Contour Surgical Inc. patents for sale “Retraction devices and methods of its use and manufacture” which includes U.S. Granted Patents US 9,999,414B2, US 10,660,630 B2, and US 20200289106 A1. The IP relates to medical device systems and methods of making and using the systems. Particularly, it relates to retraction devices for separating ribs for thoracic surgeries, as well as methods of making and using the retraction devices. The IP defines technologies for reducing tissue trauma during thoracic retraction as well as assistive technologies that aid users in the retraction process.
The technology disclosed provides the following advantages:
- The retraction device is to be designed to engage patient tissue with a flexible material that minimizes maximum forces exerted on the patients' tissues and bones.
- The retraction device is designed with an area moment of inertia and modulus of elasticity in mind to account for the engagement of more than one type of tissue in a single instance.
- The minimization of local stresses applied to the patient's tissues during thoracic retraction in turn reduce surgical damage to the patient's intercostal and inter-sternal tissue which is a notable complication for patients after surgery.
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
“Medicament Management Kit”
IPApproach, LLC, is pleased to present the exclusive patents for sale “Medicament management kit” which includes U.S. Granted Patent US 10,194,688 B2 assigned to George Roberto Jr. and G . Timothy Ryan Roberto. The IP relates to a method for a medicament management system. The medicament management system includes a main body, a lid, is pivotally coupled to the main body so as to moveable between a closed condition defining an interior housing and an open condition to access interior housing.
The technology disclosed provides the following advantages:
- A medicament management kit for managing medical marijuana, wherein all the paraphernalia necessary for managing the storage and dispensing of medical marijuana are in a convenient and durable compact kit.
- Medication management kit Improved patient use and administration of all medications, Improved percentage of patients meeting their healthcare goals.
The Medical Marijuana market is estimated to grow from USD 22.4 billion in 2020 to USD 77.04 billion by 2027, at a Compound Annual Growth Rate (CAGR) of 19.3% during the forecast period.
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
“Smoke Producing Tablet and Method of Use” and Associated Technology and Products
IPApproach, LLC is pleased to present the exclusive patents, technology, andproducts for license, partnership, or Investment of “Smoke Producing Tablet And Method Of Use” which includes US Patent 10,905,115 and US Continuation Application 17/164,777 and all Foreign Counterpart Applications, assigned to Arjesil Inc. The IP relates to compositions which produce controlled smoke upon combustion and a method of making portable smoke tablets based on that composition.
The technology disclosed provides the following advantages:
- It release controlled smoke and deliver active ingredients to any desired area or volume.
- Obviates the use of harsh chemicals and is safe to use for organic agriculture and home use.
- Used to combat insects and microbiological contamination, or just be to disinfect an area or scent a particular area.
- Suitable for combating flying insects, such as mosquitoes, flies, the species of Musca domestica, moths, ants, mites, cockroaches, silverfish, aphids, spider mites, and/or other pests.
- The slow burn times reach from one minute to several hours depending on the material of the carrier and the weight of the carrier and the load of the tablet.
- It is suitable for use in enclosed rooms, for example, in rooms, basements, warehouses, warehouses, silos, cellars, greenhouses, stables.
- It is suitable for used in outdoors, for example, gardens, terraces, agricultural land or when camping.
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
“Spectroscopic Means and Methods for Identifying Microorganisms in Culture”
IPApproach, LLC, is pleased to present the exclusive patent for sale “SPECTROSCOPIC MEANS AND METHODS FOR IDENTIFYING MICROORGANISMS IN CULTURE” which includes U.S. Granted Patents US 9,365,883 B2 & US 9,102,975 B2 Foreign Counterpart Granted Patents JP 6,204,374 B2 & IL201452A and Foreign Counterpart Patent Applications CN 201280069480.6 & EA 201400824 A1 assigned to Opticul Diagnostics Ltd. The IP relates to means and methods for identifying microorganisms in culture that rely on spectroscopic measurements of the whole cell rather than of specific chemical constituents of the cell.
The technology disclosed provides the following advantages:
- Detect and distinguish antibiotic resistant bacteria and antibiotic sensitive bacteria quickly (less than one hour) and without the need of a professional technician.
- Eliminate the interference of water contained in a sample on the experimental signal in order to provide more sensitive and accurate detection of bacteria in general and antibiotic resistant bacteria in particular.
- Accurate detection and identification of microorganisms from a primary culture plate sample without the use of additional reagents or complicated sample preparation.
- Construction of a data set such as a spectrum or interference pattern and classifies the data set, so to determine whether the microorganisms are present in the cultured sample or not.
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
“Medicinal Healing Booth System”
IPApproach LLC is pleased to present the exclusive patents for licencing or sale “Medicinal Healing Booth System” which includes U.S. Granted Patents US 9,440,041 B1 assigned to Marissa R. Lacayo. The IP relates to a system, for treating a user with medicated vapor or steam, inside a self-contained booth that is computer-operated and self-timed with various safety features to treat upper respiratory ailments. This healing booth comprises with steam generation system, temperature regulation system, sterilization system and microprocessor based control system to implement all the processes automatically.
The technology disclosed provides the following advantages:
- A medicinal healing booth system for treating a user with medicated steam for helping to relieve symptoms of colds, allergies, and asthma.
- This system provides a quick, easy way to dispense medication, such as herbal antibiotics through a vapor or steam.
- This system is a self-contained system which requires limited supervision.
- The infrared radiated heat, at a precised temperature and the patient ’s body heat (sweating), acts together safely to eliminate the cold virus.
- It self-cleans after every use with an Ultraviolet (UV) automatic system.
- It frees doctor ’s agendas a lot quicker from having to see patients with reoccurring symptoms.
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
“System to Monitor Dynamic Movement of Objects”
Exclusively offered for sale or license by IPApproach, LLC, a leading patent brokerage firm.
Any questions about this patent portfolio sale offering should be directed to:
Justin Ehrlickman | justin@ipapproach.com | 845-558-7901
Details of the offering and planned bidding process for purchasing the patent portfolio is outlined below:
THIS OFFERING IS FOR SALE AND LICENSE
- FOR SALE: 5 GROUPS – 6 US ISSUED PATENTS & 9 US APPLICATIONS
- CORE PATENTS FOR LICENSING: 5 US ISSUED PATENTS & 1 US APPLICATION
IP Approach is pleased to present the exclusive patents for the sale or license in following technology categories:
- System to monitor objects: 3 Issued, 5 Applications
- US 10,724,846 B2; US 10,856,739 B2; US 10,861,171 B2; US 20190063898 A1; US 20190274560 A1; US 20190274602 A1; US 20190385281 A1; US 20200103217 A1; US 20190374113 A1
- Authentication: 1 Issued
- US 9,916,433 B2
- Medical Parameter: 1 Issued,1 Application
- US 20190159701 A1; US 10,750,956 B2
- Medical Parameter - Glucose: 1 Issued,1 Application
- US 10,595,755 B2; US 20200232915 A1
- Cell Viability Assessment: 1 Application
- US 20200160523 A1
- CORE Available for Licensing : 5 Issued,1 Application
- US 8,638,991 B2; US 9,668,672 B2; US 10,390,729 B2; US 20190374132 A1; US 9,636,041 B2; US 10,398,314 B2
"CHELATE COMPOUNDS"
IPApproach LLC is pleased to present the exclusive patent for sale “CHELATE COMPOUNDS” which include U.S. Patent US 8,288,587 B2 assigned to Mohammad Hassan Nazaran. The IP relates to a chelate compound which comprises of nitrogen source, an acidic source, first element source including sodium, chlorine, potassium and second element source including Ca, Mg, Br, Cl.
The technology disclosed provides the following advantages,
- The chelate compounds, such as chelate nanocompounds, improves the delivery and collection of various elements and/or metal ions in all pH environments, including highly acidic and alkaline environments.
- The small size of chelate nanocompounds less than 100 nm in at least one dimension, increases the likelihood of cell wall penetration.
- The chelate nanocompunds has higher resistance against structural breakage and/or deformation in highly acidic or alkaline environments.
- The high customizability of the chelate nanocompounds to deliver or collect different elements and/or metal ions enables the chelate nanocompounds to be optimized for various uses.
- The chelate nanocompounds can be used in various environments, such as, for example, farms, orchards, treatment facilities, factories, research centers, plants, animals, and/or humans.
- The chelate compounds can reduce spoiled crop, improve soil texture, reduce underground water pollution, and increase the metabolism in plants resulting in more efficient absorption of elements in the soil and other fertilizers.
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
“Walker Adapter”
IPApproach LLC is pleased to present the exclusive patents for sale “Walker adapter” which includes U.S. Granted Patent US 8,544,486 B1 assigned to Se Sunrise Holdings LLC. The IP includes an adapter for use with a walker.
The technology disclosed provides the following advantages:
-
- The adapter has a mesh that includes a running surface for engaging soft surfaces such as sand, dirt, and the like, into which conventional walker legs generally sink.
- Member used in the adapter is constructed from any material (such as aluminum, galvanized metal, steel, stainless steel) that is durable, water-resistant, and of sufficient rigidity to maintain its integrity on uneven ground surfaces such that member does not bend or conform to the ground surface during use.
The global Walking Aids market is estimated to grow from USD 2.2 billion in 2018 to USD 3.72 billion by 2026, at a Compound Annual Growth Rate (CAGR) of 6.8% during the forecast period.
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
“Systems, Devices, and/or Methods for Managing Transdermal Patches”
IPApproach LLC is pleased to present the exclusive patent for sale “Systems, devices, and/or methods for managing transdermal patches” which includes U.S. Granted Patent US 10,661,065 B1 assigned to N Brereton Medical Technologies LLC. The IP relates to a system for manually controlling the delivery of a transdermally-delivered medication. The technology disclosed provides the following advantages:
-
- It maintain the lower dose of medication and further control the delivery flow rate of medication to the skin of patient using flux controller.
- The transdermal patch offers a continuous, sustained release of drug and avoids daily peak and trough hormone levels.
- Flux controller consists of impermeable portion containing apertures which allow the medication to permeate from patch to skin.
The Global Transdermal Skin patches market was worth $6.23 billion in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 4.5% till 2023.
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
“Orthopaedic methods or devices for non-surgical treatment of bones or joints”
IPApproach LLC is pleased to present the attached exclusive patent portfolio for sale listed in slides 6 to 8 which includes 22 U.S. Granted Patents assigned to Nordt Development Co. The IP relates to “Orthopaedic methods or devices for non-surgical treatment of bones or joints”.
- US 7062865 B1: The technology disclosed provides the following advantages:
- Provides foot comfort particularly for athletes as they continue to push their capabilities toward ever higher objectives, i.e. longer distances, higher jumps, etc.
- Provides the capture and return of energy generated naturally during the gait cycle.
- Provide a more comfortable shoe insert or insole, particularly for athletic footwear.
- The material is also preferably lightweight so as not to add to the athletes lifting burden during strenuous activity.
- US 7704219 B2: The technology disclosed provides the following advantages:
- The invention includes a rotary device for effecting adjustments in the tension of the tensioning line, thereby effecting adjustments to the wrist support.
- There is no need of hard-shell or rigid beam components.
- Provides simple hinging contraptions.
- US 7618386 B2: The technology disclosed provides the following advantages:
- Provides deflection of muscle forces.
- Provides functional shortening of muscle length.
- Provides the maintenance of neurovascular channels.
- US 7615021 B2: The technology disclosed provides the following advantages:
- Provides external support in hinge joints of the body.
- Helps address joint fatigue, pain.
- Provides the capture and return of energy generated naturally during the gait cycle.
- Advantages of side struts used include substitution of side struts having different ranges of elasticity and flexing properties for providing the desired degrees of flexibility at the hinge joint combined with degrees of rigidity in the first direction along the opposite sides of the framework.
- US 7670306 B2: The technology disclosed provides the following advantages:
-
- Provides elastically stretchable framework.
- Advantages of side struts used include substitution of side struts having different ranges of elasticity and flexing properties for providing the desired degrees of flexibility at the hinge joint combined with degrees of rigidity in the first direction along the opposite sides of the framework.
- A benefit of the openings extending from inner to outer surfaces of the framework is that these openings may permit portions of the area of the body that are in abutting engagement with the framework to breathe, especially where the inner surface directly contacts the body and no intermediate member extends there between, such as a liner
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
“MAGNETIC DEFIBRILLATOR TRAINING PAD”
IPApproach LLC is pleased to present the attached exclusive patents for sale “Magnetic defibrillator training pad” which includes U.S. Granted Patent US 9,373,271 B2 assigned to Cristine Petruzziello. The IP relates to a to defibrillator training system. More Specifically, magnetic defibrillator training pad receivable on a training dummy. The technology disclosed provides the following advantages:
- Traditional defibrillator training pads comprise a sticky adhesive that allows them to be placed on the dummy and held in place but it attracts lint, dirt, dust, and other particles which stick to the adhesive, rendering it useless. Therefore, present invention enables the use of magnetic metal on pads which allows the pads to be placed in a proper place on training dummy without falling off.
- The magnetic attached defibrillator training pads can be re-used repeatedly during training.
- Magnetic attached defibrillator doesn’t attract lint, dust and uses magnet-magnet metal connection between torso and pad.
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
“SURGICAL DEVICES FOR IMMOBILIZING SACROILIAL JOINT”
IPApproach LLC is pleased to present the attached exclusive patents for sale “Surgical devices for immobilizing sacroilial joint” which includes U.S. Patents US 10245044 B2, US 9241798 B2 assigned to Doulos Medical. The IP relates to a method of medical devices for treatment of the sacroiliac joint.
The technology disclosed provides the following advantages:
- The present invention involves insertion of graft which substantially fuse the patient's ilium and sacrum and further immobilizes the patient's SI joint.
- Helps to decrease the substantial risks which causes discomfort to the patient.
- Provides high success rate.
- Helps in eliminating and reducing the pain resulting from SI joint problems.
- Helps to reduce the painful friction between the rubbing portion of bones.
Please contact Justin Ehrlickman via email at justin@ipapproach.com or phone at 845-558-7901 to receive a Brokerage Marketing Package.
IPApproach has patents for sale in the following categories:
Advertising
Automotive & Vehicles & Trailers
Biometrics & Touch Screen
Construction
Consumer - Electrical
Consumer - Other
Data Management
Delivery & Routes
Display and Imaging
Energy
Gaming
Internet of Things (IOT)
Medical
Mobile & Telecommunications
Office Furniture / Equipment
Other
Security
Semiconductor and Packaging
Social Media
Tools & Brackets
Trademark
Video
Wireless
Other - TransactionsIP